Medros utilizes Drosophila to take a novel, whole animal approach to drug discovery for cancer metastasis and for diabetes-related diseases. We are founded on the scientifically validated premise that traditional methods of gene discovery neglect the complex tissue and cell interactions that occur in the context of a whole animal. Our whole animal approach embraces disease complexity to improve the prospects for better efficacy with lower risk for toxicity.

The specific goal of Medros is to screen drug libraries with its proprietary platform and models to identify lead compounds for cancer and diabetes indications. Medros will then take these compounds into the clinic and establish clinical proof of concept minimally through Phase II trials.